{
  "docId": "019de072-f883-7038-87b7-1190d38538fc",
  "docSlug": "b2613cd3e65595fa61ed3ce545efa4c9",
  "documentTitle": "Exscientia | Investor Presentation Deck | 37 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 37,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a multi-panel line chart layout to compare drug efficacy and toxicity across different time points and cell types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f883-7038-87b7-1190d38538fc/35",
  "deckHref": "/decks/019de072-f883-7038-87b7-1190d38538fc",
  "deckJsonHref": "/decks/019de072-f883-7038-87b7-1190d38538fc.json",
  "deckAnchorHref": "/decks/019de072-f883-7038-87b7-1190d38538fc#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.24,
        "x": 0.73,
        "y": 0.23
      },
      "kind": "callout",
      "text": "Key results: (A) EXS617 has same depth of response on ovarian cancer cells as CDK4/6 inhibitors but at lower concentrations (N=10). (B) The CDK4/6 inhibitors have greater immune cell (off-target) effects than EXS617.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8954d66d-f07d-46cb-b825-ff2e2e6bd0c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.32,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Ovarian Cancer Cell Fraction",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d0d0d4e-ab83-400f-be90-50a7ea2330fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.32,
        "x": 0.38,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Viable Cancer and Immune Cells",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a416025c-c0ec-446a-962a-c035b406b63c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "A) Shaded areas show interquartile range of estimated EC50 values across samples, at each drug and time point. Asterisks indicate significance of treatment vs. media difference in log-averages (t-test): <0.001=***, <0.01=**, <0.05=*. A and B) N=10 samples. TME = tumour microenvironment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5479b042-694b-467a-8fc8-3a762b19b117",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "TME evaluation from patient samples shows impact beyond just cancer cells",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f881fa8c-efa6-4a87-b910-fd0470eceed7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "CDK7i: Sparing immune cells in comparison to CDK4/6i",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3d4109f-680c-4f91-b5b5-607a7e23c12d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "611c0b5c-1079-431e-9230-b1b008a0f6be",
      "evidence": "chart/line: Viable Cancer and Immune Cells",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "35482908-0901-41ec-ba10-205d43a3fd15",
      "evidence": "chart/line: Ovarian Cancer Cell Fraction",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "f80d87b3-6d9a-4639-9a82-6f98ff00cde4",
      "evidence": "Direct comparison of drug efficacy and off-target effects across multiple metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 35,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5c4c8d7b-e37e-409f-8937-2163508fee37",
      "evidence": "The deck presents data on the consequences of traditional drug discovery methods on slides 24-35",
      "position": 0,
      "objective": "Highlight the consequences of not adopting Exscientia's AI-driven approach",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 37,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7b15f9dd-8590-4693-8bcf-77e7f6a4d27a",
      "evidence": "The deck presents a clear narrative around Exscientia's strategy and its benefits throughout",
      "position": 1,
      "objective": "Explain Exscientia's patient-first AI strategy and its benefits",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}